Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Literature DB >> 17709466

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Emma Huitric¹, Peter Verhasselt, Koen Andries, Sven E Hoffner.

Abstract

The diarylquinoline R207910 is in clinical development for tuberculosis treatment. The MIC(50) for 41 drug-susceptible and 44 multidrug-resistant Mycobacterium tuberculosis clinical isolates was 0.032 microg/ml. Out of 20 additional mycobacterial species, three were found to be naturally resistant to R207910 and were shown to exhibit a polymorphism in their atpE genes.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17709466 PMCID： PMC2151410 DOI： 10.1128/AAC.00181-07

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

Review 1. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.

Authors:
Journal: Am J Respir Crit Care Med Date: 1997-08 Impact factor: 21.405

2. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors: Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal: Science Date: 2004-12-09 Impact factor: 47.728

3. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.

Authors: Stephanie Petrella; Emmanuelle Cambau; Aurelie Chauffour; Koen Andries; Vincent Jarlier; Wladimir Sougakoff
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

4. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors: E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

5. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors: C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal: Nature Date: 2000-06-22 Impact factor: 49.962

6. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors: S H Siddiqi; J P Libonati; G Middlebrook
Journal: J Clin Microbiol Date: 1981-05 Impact factor: 5.948

7. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.

Authors: Marc R de Jonge; Luc H M Koymans; Jérôme E G Guillemont; Anil Koul; Koen Andries
Journal: Proteins Date: 2007-06-01

8. Mycobacterium novocastrense sp. nov., a rapidly growing photochromogenic mycobacterium.

Authors: H Shojaei; M Goodfellow; J G Magee; R Freeman; F K Gould; C G Brignall
Journal: Int J Syst Bacteriol Date: 1997-10

9. Diarylquinolines target subunit c of mycobacterial ATP synthase.

Authors: Anil Koul; Najoua Dendouga; Karen Vergauwen; Brenda Molenberghs; Luc Vranckx; Rudy Willebrords; Zorica Ristic; Holger Lill; Ismet Dorange; Jerome Guillemont; Dirk Bald; Koen Andries
Journal: Nat Chem Biol Date: 2007-05-13 Impact factor: 15.040

10. Beijing/W genotype Mycobacterium tuberculosis and drug resistance.

Authors:
Journal: Emerg Infect Dis Date: 2006-05 Impact factor: 6.883

49 in total

Review 1. The chemical biology of new drugs in the development for tuberculosis.

Authors: Clifton E Barry; John S Blanchard
Journal: Curr Opin Chem Biol Date: 2010-05-07 Impact factor: 8.822

Review 2. TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors: Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal: Future Microbiol Date: 2010-06 Impact factor: 3.165

3. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors: Barbara A Brown-Elliott; Richard J Wallace
Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191

Review 4. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.

Authors: Sangjin Hong; Peter L Pedersen
Journal: Microbiol Mol Biol Rev Date: 2008-12 Impact factor: 11.056